Clinical trials: Immune Checkpoint Inhibitors (ICIs)
Endometrial Cancer, Endometrial Adenocarcinoma
Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
This is an open-label, multi-center Phase II study of cadonilimab (AK104) combined with lenvatinib in patients with advanced endometrial cancer.
- Trial name
- NCT05824481
- Testing
- Cadonilimab, Lenvatinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Lung Neoplasms, Lung Cancer, Nonsmall Cell
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients
To evaluate the predictive value of ctDNA in response, relapse for patients treated with immune checkpoint inhibitors or targeted therapy for ALK, ROS1, MET ex14 skipping.
- Conditions
- Lung Neoplasms, Lung Cancer, Nonsmall Cell, Adenocarcinoma of Lung, Squamous Cell Lung Cancer
- Trial name
- NCT04566432
- Testing
- Observation
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
NSCLC Stage IV, NSCLC, Recurrent
Prospective Observation of Failure Patterns in NSCLC Treated With ICIs
By prospectively observing the time to the best therapeutic effect of non-small cell lung cancer after ICI treatment, the characteristics of lesion distribution when the best therapeutic effect is reached, and the phenotype of…
- Trial name
- NCT04492969
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Fudan University
Advanced Stage NSCLC, Second-line Treatment
Efficacy and Safety of High-Dose Rate Brachytherapy With Immunotherapy and Chemotherapy as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer
This is a single-center, retrospective, propensity score-matched study exploring the efficacy and safety of high-dose rate (HDR) brachytherapy combined with immune checkpoint inhibitors (ICIs) and chemotherapy as a second-line…
- Conditions
- Advanced Stage NSCLC, Second-line Treatment, Patients Without Targetable Driver Mutations
- Trial name
- HIBIC-NSCLC (NCT06518018)
- Testing
- HDR brachytherapy (30Gy single fraction), Immunotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First People's Hospital of Neijiang
Advanced Hepatocellular Carcinoma (HCC)
A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy and safety of Camrelizumab Combined with Rivoceranib Mesylate versus Investigator's Choice of Regimen in Treatment of…
- Trial name
- NCT04985136
- Testing
- camrelizumab；Rivoceranib, Rivoceranib, Sorafenib
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Esophageal Squamous Cell Carcinoma (ESCC), Neoantigen-loaded Dendritic Cell Vaccine
Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
The aim of this clinical trial is to evaluate the efficacy and safety of consolidation therapy with a neoantigen-loaded dendritic cell vaccine (NeoDC-Vac) following radical chemoradiotherapy or chemoradiation-immunotherapy in…
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Neoantigen-loaded Dendritic Cell Vaccine, Immune Checkpoint Inhibitors (ICIs)
- Trial name
- NCT06675201
- Testing
- neoantigen-loaded dendritic cell vaccine (NeoDC-Vac)
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Sichuan University
Paraneoplastic Syndromes
CICLOPS Immune Checkpoint Inhibitors Neurotoxicity: Long-term Outcomes, Predictors, and Survival.
Immune-checkpoint inhibitors (ICIs) have radically changed the therapy of cancer in recent years. ICIs promote antitumor immune response inhibiting one of the following immune checkpoints: cytotoxic T-lymphocyte antigen-4…
- Trial name
- LOPF - NIRAES (NCT05942872)
- Testing
- This is a non-interventional study. We will collect clinical data exclusively, and will do so by reviewing all available patients clinical records.
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Hospices Civils de Lyon
Esophageal Squamous Cell Carcinoma
Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer
This is a prospective, single-center, single-arm Phase II clinical study designed to evaluate the efficacy and safety of sacituzumab tirumotecan in combination with tislelizumab in patients with advanced esophageal squamous cell…
- Trial name
- NCT07811752
- Testing
- Sacituzumab Tirumotecan (SKB264) plus Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Shanghai Chest Hospital
Unresectable Cutaneous Melanoma
Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma
This first-in-human study will evaluate the safety, clinical activity, and immunologic effects of combining axelopran with nivolumab in patients with PD-1-refractory unresectable or metastatic cutaneous melanoma.
- Trial name
- MORALE-MM (NCT07631325)
- Testing
- Axelopran, Nivolumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- John Kirkwood
Hepatocellular Carcinoma, Programmed Cell Death 1
Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC
China is a high-risk area of Hepatocellular Carcinoma (HCC). Although Chinese population accounts for 18.4% of the global population, the number of new HCC patients accounting for about half of the global, which seriously…
- Conditions
- Hepatocellular Carcinoma, Programmed Cell Death 1, Effects of Immunotherapy
- Trial name
- NCT05420922
- Testing
- Lenvatinib Oral Product, PD-1 inhibitor, Local treatment
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Tongji Hospital
HCC - Hepatocellular Carcinoma
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
This trial is designed to explore the efficacy and safety of interventional therapy combined with immune checkpoint inhibitors(ICIs) and anti-vascular endothelial growth factor(VEGF) antibody/tyrosine kinase inhibitors in the…
- Trial name
- NCT07157969
- Testing
- Lenvatinib, Pembrolizumab, Atezolizumab
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Lung Cancer, Nonsmall Cell
Prediction Model of ICIs Combined With Chemotherapy in Advanced NSCLC
The reliable predictive markers to identify which patients with advanced non-small cell lung cancer tumors will achieve durable clinical benefit for chemo-immunotherapy are needed.
- Trial name
- NCT05725915
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Beijing Red Clove Public Welfare Development Center
Head and Neck Cancer, Melanoma
Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies
Two part prospective study to: 1. investigate the feasibility of performing ultra-deep sequencing of plasma derived circulating tumor DNA (ctDNA) in individual patients with advanced solid tumors who are currently being treated…
- Trial name
- SPECIAL (NCT02724488)
- Volunteers
- 14 people
- Sponsor
- University Health Network, Toronto
Primary Liver Cancer, Hepatocellular Carcinoma
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
To evaluate the predictive value of ctDNA in response, relapse for liver cancer patients treated with immune checkpoint inhibitors
- Conditions
- Primary Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Combined Hepatocellular-cholangiocarcinoma
- Trial name
- NCT05292443
- Testing
- Observation
- Where
- 5 sites in China
- Sponsor
- Geneplus-Beijing Co. Ltd.
Liver Cancer
Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs)
To evaluate the additional efficacy and safety of oral enterobacterial capsules in patients with intermediate and advanced liver cancer and treated with tyrosine kinase inhibitors (TKIs) combined with immunotherapy.
- Trial name
- NCT06563934
- Testing
- Oral enterobacterium capsules, Lenvatinib + PD-1 monoclonal antibody
- Volunteers
- 70 people
- Sponsor
- Xu Yong, MD
Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
The CR1STAL-Adaptive study is a randomized, open-label, phase II multicenter interventional trial designed to evaluate the safety and efficacy of Ivonescimab (PD-1/VEGF bispecific antibody) combined with docetaxel versus standard…
- Trial name
- NCT06951646
- Testing
- Ivonescimab, Docetaxel, Standard Treatment group
- Where
- 20 sites in China
- Volunteers
- 70 people
- Sponsor
- Second Xiangya Hospital of Central South University
ESCC
Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later Setting
This is a prospective, single-arm, exploratory, single-center clinical study designed to evaluate the efficacy and safety of becotatug vedotin (MRG003) in combination with an investigator's choice of immune checkpoint inhibitor…
- Trial name
- VISTA-ESCC (NCT07892833)
- Testing
- Becotatug vedotin (MRG003)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Advanced Lung Cancer
Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator
The main objective of this study is to evaluate the change of neutrophil to lymphocyte ratio (NLR) after 6-week treatment of immune checkpoint inhibitors (ICIs) with or without immunomodulatory drugs and recognize the effect of…
- Trial name
- NCT04352335
- Where
- Taiwan
- Volunteers
- 53 people
- Sponsor
- Chung Shan Medical University
Hepatocellular Carcinoma, Lenvatinib
Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC
Previous studies had suggested hepatic arterial infusion chemotherapy (HAIC) combined with immune checkpoint inhibitors (ICIs) and anti-angiogenic drugs had promising anti-tumor activity in unresectable hepatocellular carcinoma…
- Trial name
- NCT06435013
- Testing
- Lenvatinib
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer
Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients
This is a double-blind, randomized controlled study evaluating the efficacy and safety of HGXJT in combination with ICI-based standard treatment in lung cancer patients with bone metastases.
- Trial name
- NCT05378334
- Testing
- ICI, Chemotherapy, Bone-protecting and Mass-dispersesing Decoction
- Where
- China
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Guangzhou University of Traditional Chinese Medicine